Every approved treatment for narcolepsy — stimulants, sodium oxybate, wake-promoting agents — manages symptoms without addressing why they occur. For narcolepsy type 1, the cause is well established: the immune system destroys the brain's orexin-producing neurons, collapsing the neurochemical scaffolding of stable wakefulness. A new class of drugs called orexin receptor agonists aims to replace that missing signal, and one such drug is already under FDA review for type 1.
But narcolepsy type 2 is a different problem — or so the field has long assumed. These patients also suffer from overwhelming daytime sleepiness, yet their orexin levels typically test normal. Without a clear orexin deficit, there was little biological rationale for giving them an orexin-boosting drug. Now, results from a landmark trial suggest that reasoning was wrong.
The Vibrance-2 Results
The Vibrance-2 study, a randomized, double-blind, placebo-controlled phase 2 trial conducted by Alkermes, enrolled 93 adults with narcolepsy type 2. Participants were randomized to one of three doses of alixorexton — 10 mg, 14 mg, or 18 mg — or placebo, taken once daily for eight weeks.
The drug met both co-primary endpoints:
- Maintenance of Wakefulness Test (MWT): Patients on the 14 mg and 18 mg doses showed statistically significant improvements in sleep latency — the length of time they could stay awake in a quiet, dimly lit room. All three doses produced clinically meaningful gains over placebo.
- Epworth Sleepiness Scale (ESS): The 18 mg dose achieved statistically significant reductions in subjective daytime sleepiness after multiplicity adjustment. All dose groups showed clinically meaningful improvements from baseline.
Alixorexton was well tolerated at every dose tested. No serious adverse events were reported. The most common side effects were pollakiuria (frequent urination), insomnia, and dizziness — all mild to moderate.
Why This Matters Beyond the Numbers
The Vibrance-2 data represent a conceptual shift, not just a clinical one. This is the first large, randomized phase 2 study to demonstrate that an orexin 2 receptor agonist can drive clinically meaningful improvement in a patient population without known orexin deficiency.
That finding raises a fundamental question: if narcolepsy type 2 patients have normal orexin levels, why does amplifying orexin signaling help them?
Several hypotheses are emerging. One possibility is that standard cerebrospinal fluid tests are too crude to detect subtle orexin dysfunction — patients may have localized deficits or receptor-level signaling problems that don't register in a lumbar puncture. Another is that boosting orexin transmission above baseline simply strengthens a wake-promoting circuit that is functionally weak, even if the neuropeptide itself is present in normal concentrations.
Either way, the results suggest that the binary framework — type 1 means orexin deficiency, type 2 means something else — may be an oversimplification.
A Disease That Has Been Underserved
Narcolepsy type 2 affects an estimated 20 to 34 people per 100,000, though the true prevalence is likely higher because the condition is frequently misdiagnosed as depression, chronic fatigue, or idiopathic hypersomnia. Unlike type 1, it lacks a diagnostic biomarker — the diagnosis rests on clinical criteria and an overnight sleep study followed by a daytime nap test.
Treatment options have historically been borrowed from the type 1 playbook: modafinil, amphetamines, and, more recently, sodium oxybate. No drug has ever been specifically developed or approved for narcolepsy type 2. Alixorexton could change that. Alkermes has initiated a global phase 3 program — the Brilliance studies — enrolling patients with both type 1 and type 2 narcolepsy as of mid-2026.
The detailed Vibrance-2 results, including exploratory endpoints on cognition and fatigue, are being presented at the SLEEP 2026 annual meeting in Baltimore, where Alkermes is sharing 26 research abstracts.
What This Means for Patients
For the roughly half of narcolepsy patients who have type 2, the Vibrance-2 data offer two kinds of hope. The first is practical: a drug designed around the biology of wakefulness, rather than a stimulant that forces alertness through a blunter mechanism, may eventually reach them. The second is deeper: for the first time, research is suggesting that their disease shares a mechanistic thread with type 1, which could accelerate development of targeted therapies and bring the condition closer to the clinical and research attention it has long lacked.
